saRNA delivery system, method for preparing the same, and use

A novel saRNA delivery system using microvesicles with viral envelope proteins addresses the limitations of VRP systems by ensuring safe and efficient gene and protein delivery, achieving sustained expression and tissue-targeted therapy.

JP2026516956APending Publication Date: 2026-05-27ZHEJIANG FREE TRADE ZONE HONGAN BASE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
ZHEJIANG FREE TRADE ZONE HONGAN BASE BIOTECHNOLOGY CO LTD
Filing Date
2024-04-11
Publication Date
2026-05-27

AI Technical Summary

Technical Problem

Existing gene delivery systems, particularly VRP delivery systems, face challenges such as genetic recombination risks, low transfection efficiency, and immunogenicity, limiting their application in gene therapy and protein drug delivery due to the presence of viral structural proteins.

Method used

A novel saRNA delivery system using a transfection system of two plasmids to generate microvesicles containing saRNA and viral envelope proteins, which do not include capsid proteins, enabling efficient and targeted delivery of saRNA without generating progenitor viruses.

Benefits of technology

The system achieves high-efficiency, low-immunogenic saRNA delivery, allowing sustained protein expression and tissue-targeted delivery, overcoming the limitations of existing VRP systems by avoiding viral nucleoprotein components and enabling safer, more effective gene and protein therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026516956000001
    Figure 2026516956000001
  • Figure 2026516956000002
    Figure 2026516956000002
  • Figure 2026516956000003
    Figure 2026516956000003
Patent Text Reader

Abstract

This disclosure belongs to the field of biotechnology and specifically relates to a method for constructing an saRNA microvesicle delivery system. The method comprises the steps of (1) designing an saRNA expression vector 1 and a membrane protein expression vector 2, (2) co-transfecting an expression vector 1 and an expression vector 2 into a host cell, and (3) culturing the host cell and isolating microvesicles containing saRNA, wherein the saRNA contains a target gene sequence, the replicon of the saRNA expression vector is an alphavirus replicon, and the microvesicles do not contain a capsid protein. This system can efficiently deliver saRNA into cells or the body and achieve the expression of a target protein. Furthermore, by improving different elements of this delivery system, a highly efficient and less immunogenic modular platform for different diseases and targets can be developed. This delivery system has the potential to complement existing viral and lipid nanoparticle delivery vector toolkits and shows promising future application potential.
Need to check novelty before this filing date? Find Prior Art